drug_type
RELEVANT_DRUG
intervention_type
Genetically modified cellular therapy (CAR T)
drug_description
Autologous T cells genetically modified to express a chimeric antigen receptor targeting BCMA (TNFRSF17) on plasmablasts/plasma cells to eliminate antibody-secreting cells and modulate autoimmunity.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are genetically engineered to express a chimeric antigen receptor that recognizes BCMA (TNFRSF17) on plasmablasts and plasma cells. Upon antigen binding, CAR signaling activates the T cells to kill BCMA+ cells via cytotoxic effector functions and cytokine release, depleting antibody-secreting cells and reducing pathogenic autoantibodies to modulate autoimmunity.
drug_name
BCMA CAR-T cells
nct_id_drug_ref
NCT06428188